Risk to exclusivity from failure to register or invalidation of patents and third-party claims
First written in FY2024. 1 of 2 entries say "Worsened", first in FY2025. Latest entry: FY2025.
Chordia Therapeutics moved to the "Worse" side of this theme in 2025, 5 years after the typical company in this theme (2020).
1 other company's latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「In addition, with respect to PCT/JP2017/016717, the substance patent for the CLK inhibitor, certain defects existed in part of the patent specification when the application was filed. After obtaining opinions from external experts, we have addressed the matter in cooperation with the patent firm and Takeda Pharmaceutical Company, the licensor, and registration has proceeded in each country without issue to date. However, the possibility that an opposition or patent invalidation proceeding could be filed in the future on the basis of those defects cannot be ruled out.」
In addition to the conventional general risks of non-registration and invalidation, the risk of oppositions and patent invalidation proceedings arising from defects in the CLK substance patent specification has become more concrete. - FY2024First statedAnnual report
「There is no guarantee that all of the patents currently under application and held by us will be registered. Even if a patent is registered, all or some of its claims may be invalidated through a patent opposition or patent invalidation trial, potentially resulting in the loss of exclusivity.」
The risk that business exclusivity could be impaired by non-registration of pending patents, post-registration oppositions or patent invalidation proceedings, and intellectual property disputes with third parties was identified.